Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ichiro Nakashima

Showing results (11-20 of 251) with videos related to

Pageof 26
Sort By:
Brain and Nerve = Shinkei Kenkyu No Shinpo|July 21, 2022
[COVID-19 Vaccines for Patients with Neuroimmunological Diseases]Ryo Ogawa, Ichiro Nakashima
International Immunology|September 16, 2017
Efficiency of antibody therapy in demyelinating diseasesTetsuya Akaishi, Ichiro Nakashima
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 10, 2014
[Rituximab (anti-CD20) in neurological disorders]Tetsuya Akaishi, Ichiro Nakashima
Neurology(R) Neuroimmunology & Neuroinflammation|April 26, 2017
Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?Takashi Yamamura, Ichiro Nakashima
Neurology(R) Neuroimmunology & Neuroinflammation|October 24, 2014
Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?Kazuo Fujihara, Ichiro Nakashima
Brain and Nerve = Shinkei Kenkyu No Shinpo|April 11, 2018
[Autoantibodies in Neuromyelitis Optica Spectrum Disorders]Ichiro Nakashima, Tetsuya Akaishi
Neurology|June 8, 2021
Reader Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?Juichi Fujimori, Ichiro Nakashima
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 14, 2020
[Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic]Masashi Nakamura, Ichiro Nakashima
Journal of Medical Economics|November 8, 2024
Employment status of multiple sclerosis patients in JapanIchiro Nakashima, Nozomu Tanaka
Heliyon|March 28, 2024
Brain volume loss in Japanese patients with multiple sclerosis is present in the early to middle stage of the diseaseJuichi Fujimori, Ichiro Nakashima
Pageof 26

Showing results (11-20 of 251) with videos related to

Sort By:
Pageof 26
Brain and Nerve = Shinkei Kenkyu No Shinpo|July 21, 2022
[COVID-19 Vaccines for Patients with Neuroimmunological Diseases]Ryo Ogawa, Ichiro Nakashima
International Immunology|September 16, 2017
Efficiency of antibody therapy in demyelinating diseasesTetsuya Akaishi, Ichiro Nakashima
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 10, 2014
[Rituximab (anti-CD20) in neurological disorders]Tetsuya Akaishi, Ichiro Nakashima
Neurology(R) Neuroimmunology & Neuroinflammation|April 26, 2017
Foveal thinning in neuromyelitis optica: A sign of retinal astrocytopathy?Takashi Yamamura, Ichiro Nakashima
Neurology(R) Neuroimmunology & Neuroinflammation|October 24, 2014
Secondary progression and innate immunity in NMO: A possible link to alemtuzumab therapy?Kazuo Fujihara, Ichiro Nakashima
Brain and Nerve = Shinkei Kenkyu No Shinpo|April 11, 2018
[Autoantibodies in Neuromyelitis Optica Spectrum Disorders]Ichiro Nakashima, Tetsuya Akaishi
Neurology|June 8, 2021
Reader Response: Teaching Video NeuroImages: Pathologic Yawning: A Sign of Brainstem Involvement in Acute Disseminated Encephalomyelitis?Juichi Fujimori, Ichiro Nakashima
Brain and Nerve = Shinkei Kenkyu No Shinpo|October 14, 2020
[Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic]Masashi Nakamura, Ichiro Nakashima
Journal of Medical Economics|November 8, 2024
Employment status of multiple sclerosis patients in JapanIchiro Nakashima, Nozomu Tanaka
Heliyon|March 28, 2024
Brain volume loss in Japanese patients with multiple sclerosis is present in the early to middle stage of the diseaseJuichi Fujimori, Ichiro Nakashima
Pageof 26